Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: tool dude who wrote (123546)	12/1/2003 9:25:29 AM
From: Taki	Read Replies (1) \| Respond to of 150070

OFCC.05x.06.News B: Ofek Capital To Relaunch Mortgage Banking Services Subsidiary inal Acquisition Expected To Be Accretive to Earnings B: Ofek Capital To Relaunch Mortgage Banking Services Subsidiary Final Acquisiti n Expected To Be Accretive to Earnings ( PRIMEZONE ) TORONTO, Dec 01, 2003 (PRIMEZONE via COMTEX) -- Ofek Capital Corp. (Pink Sheets:OFCC) announces that Ofek, through its wholly owned subsidiary, Mortgage Bankers of North America of California, is in the process of evaluating the purchase of a Southern California based mortgage banking firm, to enable Ofek to rapidly reenter the lucrative mortgage banking market. Shalom Romm, the CEO of Ofek notes: "Ofek is now evaluating and conducting initial due diligence on a number of possible viable options, to allow Ofek to reenter the mortgage-banking arena. Although we have our own business plan to implement upon reentering this very rewarding and lucrative sub prime market, we see a benefit in jump-starting this process by purchasing an already operating, profitable company, which is currently generating respectable and healthy revenues. Any final decision will most assuredly be accretive to earnings." Shalom Romm further notes that "Mortgage Bankers of North America, Ofek's California based mortgage banking subsidiary in waiting, has additional expertise and resources including seasoned management and personnel to enhance the bottom line of any final acquisition which, in turn, will build upon Ofek's profitability success already recognized this year." About Ofek Capital Ofek www.OfekCapital.com is a North American financial services company that operates within the sub-prime lending and financing market. Ofek believes that the sub-prime market is the most lucrative niche in the financial services industry. Ofek Capital subsidiaries include: AJM Leasing, Mortgage Bankers of North America and SecondaryMarkets. -- Ofek leases used cars through its Ontario subsidiary, AJM Leasing -- Mortgage Bankers of North America, a California subsidiary, anticipates offering traditional mortgage banking services in 24 states -- SecondaryMarkets, a California subsidiary, anticipates the development of a proprietary, patent pending, automated submission and lending approval software system. It will be state-of-the-art and capable of generating immediate loan approval from multiple loan providers This release as well as the interview and statements made during it contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, which reflect management's expectations regarding Ofek's future growth, results of operations, performance and business prospects and opportunities. These statements reflect management's current beliefs and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. A number of factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. Ofek Capital Corp. takes no obligation to update or correct any or such forward-looking statements. SOURCE: Ofek Capital Corp. By Staff CONTACT: CLX & Associates, Inc. Robert Weidenbaum, President Phone 1 800 860 8241 email ir@OfekCapital.com (C) 2003 PRIMEZONE, All rights reserved. -0- INDUSTRY KEYWORD: Financial Services SUBJECT CODE: BANKING Company Announcement Product Services Announcement * end of story *

To: tool dude who wrote (123546)	12/1/2003 9:28:07 AM
From: Taki	Respond to of 150070

TFCT .051 news B: Bayer AG Adds to Inventory of 21st Century's ProMags B: Bayer AG Adds to Inventory of 21st Century's ProMags LAS VEGAS, Dec 1, 2003 (BUSINESS WIRE) -- James Branch, President of 21st Century Technologies' (OTCBB:TFCT) wholly-owned subsidiary, Trident Technologies, Inc. announced today that Bayer AG (NYSE:BAY) has purchased a ProMag Kit, adding to its inventory of ProMags. Bayer is a major international manufacturer of a broad spectrum of medicines and chemicals from the most sophisticated new anti-biotics to familiar aspirin. The new ProMag was purchaed by Bayer's chemical division. "Ease of use, dependability and experience with ProMag led to these new sales," Mr. Branch stated. "It is important to note that these sales were to Bayer's corporate establishment in the U. S., as opposed to a particular factory or plant site. Bayer plans to place these ProMags at points they will determine at the corporate level to be most appropriate. The value of our ProMag/SeaPatch products are being recognized by major corporations all over the word now. I expect that the Bayer sale shall be followed by similar ones, originating at the highest level of corporate operations. This is a major step towards gaining broad recognition for ProMag and SeaPatch." ProMag and its marine-engineered brother, SeaPatch, are rare-earth permanent magnet powered leak and rupture sealing devices, especially appropriate for HAZMAT applications. They are in use by many major corporations, such as Bayer, Dow, Union Pacific Railroadand and ExxonMobil. Trident also sells the magnets to special specification. They are employed by the U. S. Navy and the Canadian Military Authority. Safe Harbor Statement The statements made by 21st Century Technologies Inc. (the "Company") may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of the Company. Actual results could differ materially from those projected due to risks such as changes in interest rates, market competition, our ability to generate orders and various other business risks. SOURCE: 21st Century Technologies, Inc. CONTACT: Equitilink, Inc. Ron Garner, 877-788-1940 Customize your Business Wire news & multimedia to match your needs. Get breaking news from companies and organizations worldwide. Logon for FREE today at www.BusinessWire.com. Copyright (C) 2003 Business Wire. All rights reserved. -0- KEYWORD: NEVADA INDUSTRY KEYWORD: PHARMACEUTICAL TRANSPORTATION GOVERNMENT AEROSPACE/DEFENSE PRODUCT * end of story *

To: tool dude who wrote (123546)	12/1/2003 9:30:19 AM
From: Taki	Read Replies (3) \| Respond to of 150070

HTDS.042B:Tubecin Passes Toxicity Trials! B: Hard to Treat Diseases Incorporated -- HTDS -- Announces: Tubercin Passes Tox city Trials! DELRAY BEACH, Fla., Dec 1, 2003 (BUSINESS WIRE) -- Hard to Treat Diseases Incorporated (Pink Sheets:HTDS) previously announced Friday, November 28th, that the spokesperson for the independent medical group conducting the testing for HTTD (HTDS) has advised HTTD that Tubercin(R) has passed the toxicity tests required to proceed to the live cancer trials. Testing Tubercin(R) on live Melanoma, Lung and Breast cancer cells will begin immediately. The President and CEO, Mr. Colm J. King met with the spokesperson of the medical group at their offices in Oklahoma City. Mr. King was advised that the tests were conducted under strict FDA (Federal Drug Administration) guidelines. Full test results will be available at the corporate offices as soon as the reports and findings are printed. "These are the most promising results to date regarding Tubercin(R) and we're looking forward to additional positive results in the near future," stated Mr. King. "These tests prove that Tubercin(R) is non-toxic and is the first step on the way to human clinical trials as well as the first positive breakthrough conducted in the United States with an independent medical group for Tubercin(R)." Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated ("HTTD") holds the international marketing rights, except South Korea, to Tubercin(R), a patented immunostimulant developed for combating Cancer under medical patent (US Patent 6,274,356). The unique properties unlike other cancer products are clearly stated in the abstract summary of the patent... "A carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan structure extracted from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects." Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. SOURCE: Hard to Treat Diseases Incorporated CONTACT: Hard to Treat Diseases Incorporated, Delray Beach Colm King, 561-272-6900 Colm@httddirect.com Customize your Business Wire news & multimedia to match your needs. Get breaking news from companies and organizations worldwide. Logon for FREE today at www.BusinessWire.com. Copyright (C) 2003 Business Wire. All rights reserved. -0- KEYWORD: FLORIDA INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL * end of story *